The Challenges of Treating FLT3-ITD AML

Video

Mark J. Levis, MD, PhD, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia.

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

Clinical Pearls:

  • While an AML patient with a low white blood cell count can be maintained with transfusions and antibiotics, the population of patients with a FLT3-ITD mutation are difficult to palliate
  • The majority of patients with a high white blood cell count and a FLT3-ITD mutation can be treated into remission but they will eventually relapse
  • Physicians attempt to keep these patients in remission long enough to be able to get a transplant
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
A panel of 3 experts on GVHD
A panel of 3 experts on GVHD
Related Content